Medicare AdvantageCoverageMedium impact
MA08.192a, Belantamab mafodotin-blmf (Blenrep)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Jul 1, 2026
We identified it
Jul 2, 2026
Summary
This is a Medicare Advantage policy update for Belantamab mafodotin-blmf (Blenrep), a monoclonal antibody used in oncology. The policy became effective on July 1, 2026. Without access to the full policy text, specific coverage criteria, prior authorization requirements, or billing code changes cannot be determined from the provided information.
Action Required
By June 15, 2026: Billing and clinical teams must obtain and review the complete MA08.192a policy from the source URL to identify: (1) coverage criteria and medical necessity requirements, (2) prior authorization requirements and submission process, (3) applicable HCPCS codes (likely J-codes for this biologic), and (4) any documentation requirements. Update billing system rules, prior authorization workflows, and provider/staff training materials accordingly before the July 1, 2026 effective date. Failure to implement required prior authorization or billing changes may result in claim denials for Blenrep administrations.